An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages 18 Febr. 2021

Diese Faktenboxen sollen Ihnen helfen, Nutzen und Schaden einer Schutzimpfung gegen COVID-19 abzuwägen. Die Informationen und Zahlen stellen keine endgültige Bewertung dar. Sie basieren auf den derzeit besten wissenschaftlichen Erkenntnissen

AstraZeneca-SKBio in South Korea and Serum Institute of India

INFO Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019)–mit mRNA-Impfstoffen – Erklärung für die Formulare

INFO Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019)–mit Vektor-Impfstoff –

Februrar 2021

Manufacturers: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks

On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend

Vaccinator's Manual. MODERNA Vaccine

Vaccinator's Manual. Pfizer-BioNTech Comirnaty Vaccine